BACKGROUND: Current diagnosis of allergy and asthma to cat is confirmed using cat dander extract (CDE). We have previously engineered a recombinant major cat allergen, rFel d 1, with properties identical to the natural molecule. OBJECTIVE: The aim of the study was to evaluate IgE and IgG4 antibodies to rFel d 1 among sera from cat-allergic children and adults suffering from asthma and/or rhinoconjunctivitis (RC) in populations from Sweden and Austria. METHODS: Cat-allergic children and adults from Sweden (n=27 and 31, respectively) and Austria (n=41 and 41) with RC and/or asthma were selected. Sera were tested for IgE and IgG4 antibodies to CDE and rFel d 1 by CAP, and IgE to rFel d 1 by ELISA. Healthy subjects and non-cat-allergic patients (n=75) were included as controls. RESULTS: There was a high correlation between IgE responses to rFel d 1 and CDE among the 140 patients (r(s)=0.85, P<0.001); however, measured levels to rFel d 1 were on average 30% higher (P<0.0001). Ninety-eight percent of patients and none of the controls showed IgE to rFel d 1 and there was a threefold increased risk of asthma for half of the children with the highest IgE levels [odds ratio 3.23; 95% confidence interval (CI), 1.19-8.79] by ELISA. IgE responses to rFel d 1 among children with asthma were higher (median 19.4 kU/L) compared with children with RC (median 6.6 kU/L, P<0.05) and adults with asthma (median 3.0 kU/L, P<0.01). Furthermore, children with asthma displayed higher IgG4 levels than the asthmatic adults. CONCLUSION: A single recombinant molecule, rFel d 1, is at least as sensitive for in vitro diagnostics of cat allergy as the current extract-based test. Elevated IgE antibody levels to Fel d 1 are suggested to be a risk factor for asthma in cat-allergic children.
BACKGROUND: Current diagnosis of allergy and asthma to cat is confirmed using cat dander extract (CDE). We have previously engineered a recombinant major cat allergen, rFel d 1, with properties identical to the natural molecule. OBJECTIVE: The aim of the study was to evaluate IgE and IgG4 antibodies to rFel d 1 among sera from cat-allergic children and adults suffering from asthma and/or rhinoconjunctivitis (RC) in populations from Sweden and Austria. METHODS: Cat-allergic children and adults from Sweden (n=27 and 31, respectively) and Austria (n=41 and 41) with RC and/or asthma were selected. Sera were tested for IgE and IgG4 antibodies to CDE and rFel d 1 by CAP, and IgE to rFel d 1 by ELISA. Healthy subjects and non-cat-allergic patients (n=75) were included as controls. RESULTS: There was a high correlation between IgE responses to rFel d 1 and CDE among the 140 patients (r(s)=0.85, P<0.001); however, measured levels to rFel d 1 were on average 30% higher (P<0.0001). Ninety-eight percent of patients and none of the controls showed IgE to rFel d 1 and there was a threefold increased risk of asthma for half of the children with the highest IgE levels [odds ratio 3.23; 95% confidence interval (CI), 1.19-8.79] by ELISA. IgE responses to rFel d 1 among children with asthma were higher (median 19.4 kU/L) compared with children with RC (median 6.6 kU/L, P<0.05) and adults with asthma (median 3.0 kU/L, P<0.01). Furthermore, children with asthma displayed higher IgG4 levels than the asthmatic adults. CONCLUSION: A single recombinant molecule, rFel d 1, is at least as sensitive for in vitro diagnostics of cat allergy as the current extract-based test. Elevated IgE antibody levels to Fel d 1 are suggested to be a risk factor for asthma in cat-allergic children.
Authors: Anna Pomés; Jill Glesner; Agustin Calatroni; Cindy M Visness; Robert A Wood; George T O'Connor; Meyer Kattan; Leonard B Bacharier; Lisa M Wheatley; James E Gern; William W Busse Journal: J Allergy Clin Immunol Date: 2019-06-13 Impact factor: 10.793
Authors: Olga Elisyutina; Elena Fedenko; Raffaela Campana; Alla Litovkina; Nataliya Ilina; Dmitry Kudlay; Evgenii Egorenkov; Valeriy Smirnov; Rudolf Valenta; Christian Lupinek; Musa Khaitov Journal: Allergy Date: 2019-06-26 Impact factor: 13.146
Authors: Angelico Mendy; Jesse Wilkerson; Päivi M Salo; Richard D Cohn; Darryl C Zeldin; Peter S Thorne Journal: J Allergy Clin Immunol Pract Date: 2018-04-21
Authors: Miguel Tortajada-Girbés; María Mesa Del Castillo; Helena Larramona; José Manuel Lucas; Montserrat Álvaro Lozano; Ana Isabel Tabar; Begoña Soler López; Ana Martínez-Cañavate Journal: Eur J Pediatr Date: 2019-08-14 Impact factor: 3.183
Authors: Jurgen Herre; Hans Grönlund; Heather Brooks; Lee Hopkins; Lisa Waggoner; Ben Murton; Monique Gangloff; Olaniyi Opaleye; Edwin R Chilvers; Kate Fitzgerald; Nick Gay; Tom Monie; Clare Bryant Journal: J Immunol Date: 2013-07-22 Impact factor: 5.422
Authors: Katarzyna Niespodziana; Margarete Focke-Tejkl; Birgit Linhart; Vera Civaj; Katharina Blatt; Peter Valent; Marianne van Hage; Hans Grönlund; Rudolf Valenta Journal: J Allergy Clin Immunol Date: 2011-03-16 Impact factor: 10.793
Authors: Anna Asarnoj; Carl Hamsten; Konrad Wadén; Christian Lupinek; Niklas Andersson; Inger Kull; Mirela Curin; Josep Anto; Jean Bousquet; Rudolf Valenta; Magnus Wickman; Marianne van Hage Journal: J Allergy Clin Immunol Date: 2015-12-10 Impact factor: 10.793
Authors: Ola B Nilsson; Theresa Neimert-Andersson; Mattias Bronge; Jeanette Grundström; Ranjana Sarma; Hannes Uchtenhagen; Alexey Kikhney; Tatyana Sandalova; Erik Holmgren; Dmitri Svergun; Adnane Achour; Marianne van Hage; Hans Grönlund Journal: PLoS One Date: 2014-10-29 Impact factor: 3.240
Authors: Giorgio Walter Canonica; Ignacio J Ansotegui; Ruby Pawankar; Peter Schmid-Grendelmeier; Marianne van Hage; Carlos E Baena-Cagnani; Giovanni Melioli; Carlos Nunes; Giovanni Passalacqua; Lanny Rosenwasser; Hugh Sampson; Joaquin Sastre; Jean Bousquet; Torsten Zuberbier Journal: World Allergy Organ J Date: 2013-10-03 Impact factor: 4.084